Patron Exim
- Market cap
- ₹ 5 Cr.
- P/E
- 19.7x
- P/B
- 0.11x
- 52-week range
- 1.42 – 5.19
- ROE
- −3%
- ROCE
- −2.7%
- Dividend yield
- 0%
- Debt / equity
- 0.05
- Sector
- Chemicals & Petrochemicals
- Industry
- Trading - Chemicals
- Listed on
- BSE SME
About
Patron Exim Limited is an India-based company, which is engaged in the trading and distribution of a range of pharmaceutical raw material which is also known as active pharmaceutical ingredients (APIs), industrial, excipient and solvents. The Company's product portfolio comprises of around 150 APIs, excipient, pharma chemicals and intermediates. It also trades in a variety of chemicals, such as petrochemicals, dyes and pigment chemicals, paints and specialty chemical, agro chemicals, oil and refinery chemicals, foam and adhesive, plywood and laminates chemical. The range of chemicals also includes food industry and water treatment chemicals, resins and plastics chemicals, polymers and additives, and others. The Company's products include L Glutathione Reduced, N Acetyl L Cystine, L Glutamine, N Acetyl L Tyrosine, L Carnosine, Acetone, L Arginine Base, Aerosil - 200, L Alanine, Aspartame, L Cystine Hcl Mono, Bronopol, L Cystine Base, Cm-1000, L Valine, Calcium CMC and L Leucine.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Trading - Chemicals: 16 companies →Patron Exim against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.7 against a typical 22.4: cheaper than most peers (1st = cheapest).7th of 16
- Sales growth−90.8% against a typical +27.6% from a year earlier.12th of 13
- Profit growth−286.4% against a typical +34.8% from a year earlier.10th of 10
- Share price, 3 months+4.3% against a typical +0.3%.4th of 15
- Size₹ 5 Cr. market value against a typical ₹ 215.2 Cr. (1st = largest).16th of 16
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 9 | 4 | 1 | 5 | 0 | 24 | 24 | 0 |
| Expenses | 3 | 9 | 8 | 4 | 5 | 0 | 24 | 24 | 2 |
| Operating Profit | 0 | 1 | −5 | −3 | 0 | −0 | 0 | −0 | −1 |
| OPM % | 12.1% | 6.2% | −130.6% | −228.6% | 2.6% | — | 1.1% | −0.1% | −232.7% |
| Other Income | 1 | 0 | 6 | 3 | 1 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 1 | 1 | 0 | 1 | −0 | 0 | 0 | −1 |
| Tax % | 28.9% | 28.6% | 28.6% | 30% | 26.3% | 12% | 11.1% | 50% | 0% |
| Net Profit | 1 | 1 | 1 | 0 | 1 | −0 | 0 | 0 | −1 |
| EPS in Rs | — | 0.39 | 0.34 | 0.03 | 0.25 | −0.12 | 0.14 | 0 | −0.47 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 23%
- TTM
- −1%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −1,657%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −43%
- TTM
- —
- 10 Years
- —
- 5 Years
- 1%
- 3 Years
- 0%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Patron Exim | ₹ 2.16 | ₹ 5 Cr. | 19.7x | 0.1x | −3% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 25.1x | 2.4x | 9.9% | 10.4% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 64.3x | 12.6x | 21.4% | 18% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.5x | 5x | 17.2% | 28.7% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 54.3x | 1.5x | 9.8% | 11.5% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.3x | 5.4x | 16.7% | 15% |
Management
- Hardikkumar Patel
- Chief Financial Officer
- Narendrakumar Gangaramda Patel
- Managing Director, Director
Prices are delayed and for information only. Nothing on this page is investment advice.